WA
VRTX icon

Whipplewood Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Whipplewood Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.9K Buy
217
+210
+3,000% +$97.9K 0.05% 192
2025
Q4 		$3.17K Buy
+7
New +$3.02K ﹤0.01% 322
2025
Q3 		– Sell
-589
Closed -$262K – 1140
2025
Q2 		$262K Buy
589
+5
+0.9% +$2.3K 0.14% 139
2025
Q1 		$266K Buy
584
+250
+75% +$117K 0.16% 134
2024
Q4 		$135K Buy
+334
New +$155K 0.08% 201

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Whipplewood Advisors's VRTX Position: Q1 2026 in Review

Whipplewood Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3,000% in Q1 2026, buying an estimated $97.9K and bringing the position to 217 shares worth $96.9K. The position accounts for 0.05% of the portfolio, ranked #192.

Whipplewood Advisors first reported a position in VRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $266K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Whipplewood Advisors held 217 shares of Vertex Pharmaceuticals worth $96.9K as of Q1 2026.
  • Whipplewood Advisors bought 210 Vertex Pharmaceuticals shares in Q1 2026, an estimated $97.9K.
  • Vertex Pharmaceuticals made up 0.05% of Whipplewood Advisors's portfolio in Q1 2026, its #192 holding.
  • Whipplewood Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Whipplewood Advisors's Vertex Pharmaceuticals position peaked at $266K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Whipplewood Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.